The Natsimbio holding (part of the Rostec Group) has developed and started production of the domestic drug BioGam. It is intended for the therapy of patients with primary and secondary immunodeficiencies. This was reported by the press service of the state corporation.
BioGam is included in the list of vital medicines, its production will replace imported analogues on the Russian market. Today, it is the only Russian intravenous human immunoglobulin with a concentration of 10%.
Drugs in this dosage are crucial for the quality of life of patients with immunodeficiencies. The fact is that a high concentration allows you to achieve optimal results in the treatment of immunodeficiencies with smaller volumes of the injected drug and in a shorter time.
The first batch of 5 thousand packages will arrive this year. Production volumes are planned to increase in 2025.
Earlier www1.ru reported that Active Component will build a pharmaceutical substance plant in St. Petersburg by 2025.
Read materials on the topic:
New antibiotics will appear in Russia
Russian scientists have created a wine that protects the kidneys from X-ray radiation
Now on home
